Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients

June 4, 2013

Primary Outcome Measures:

Expression of TUBB3 and BRCA1 in MPM tumor tissue by immunohistochemistry and RT-PCR. [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Association of expression of TUBB3 and BRCA1 with clinical outcome (response, survival) . [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Eligibility Criteria

Study Population

Malignant pleural mesothelioma patients treated with vinorelbine as a second or later line chemotherapy with at least an objective response evaluation.

Inclusion Criteria:

MPM patients treated with vinorelbine in the ≥ second line setting will be retrospectively analyzed
Patients will be selected based on the availability of tumor tissue

Exclusion Criteria:

CONTACT INFORMATION

Name*

First Last

Email*

Phone*

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Have you received a diagnosis?*

Yes

DIAGNOSIS

Diagnosis?*

Date of Diagnosis*

Comments*

This field is for validation purposes and should be left unchanged.

Quick Facts

Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact